Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Jiang, Tao; Shi, Jinpeng; Dong, Zhengwei; Hou, Likun; Zhao, Chao; Li, Xuefei; Mao, Beibei; Zhu, Wei; Guo, Xianchao; Zhang, Henghui; He, Ji; Chen, Xiaoxia; Su, Chunxia; Ren, Shengxiang; Wu, Chunyan; Zhou, Caicun

doi:10.1186/s13045-019-0762-1

Table 2 Univariate and multivariate analyses of clinical parameters on disease-free survival and overall survival

From: Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Factor	Univariate analysis			Multivariate analysis
Factor	HR (log rank)	95% CI	P value	HR (log rank)	95% CI	P value
Disease-free survival
Sex (female/male)	0.818	0.416–1.606	0.559
Age (≥ 65/< 65)	1.030	0.742–1.429	0.862
Smoking (yes/no)	0.892	0.632–1.257	0.513
PS (≥ 1/0)	1.092	0.759–1.571	0.636
Stage (II–III/I)	1.425	1.028–1.973	0.033	1.614	1.156–2.255	0.005
Pleural invasion (yes/no)	1.629	0.900–2.950	0.107
Vascular invasion (yes/no)	1.674	0.819–3.420	0.158
Differentiation (high/non-high)	1.080	0.505–2.309	0.842
PD-L1 (positive/negative)	0.702	0.474–1.041	0.141
CD8⁺ TIL (positive/negative)	0.632	0.444–0.898	0.010	0.711	0.429–1.180	0.187
TMB (> median/≤ median)	1.454	1.047–2.019	0.040	1.122	0.652–1.929	0.677
PD-L1 negative and TMB > median VS. others	1.533	1.097–2.140	0.021	1.176	0.708–1.954	0.530
PD-L1 negative and TMB ≤ median VS. others	0.884	0.633–1.235	0.470
PD-L1 positive and TMB ≤ median VS. others	0.506	0.272–0.938	0.031	0.506	0.261–0.979	0.043
PD-L1 positive and TMB > median VS. others	0.972	0.611–1.544	0.903
CD8⁺ TIL negative and TMB > median VS. others	2.224	1.405–3.520	0.005	1.416	0.695–2.888	0.338
CD8⁺ TIL negative and TMB ≤ median VS. others	1.102	0.705–1.720	0.670
CD8⁺ TIL positive and TMB ≤ median VS. others^#	0.629	0.441–0.898	0.011
CD8⁺ TIL positive and TMB > median VS. others	1.070	0.767–1.495	0.689
Overall survival
Sex (female/male)	1.012	0.317–3.229	0.984
Age (≥ 65/< 65)	1.252	0.758–2.068	0.381
Smoking (yes/no)	1.038	0.604–1.785	0.892
PS (≤ 1/0)	0.995	0.562–1.761	0.987
Stage (II–III/I)	2.952	1.685–5.172	< 0.001	2.844	1.606–5.038	< 0.001
Pleural invasion (yes/no)	1.425	0.613–3.309	0.411
Vascular invasion (yes/no)	2.214	0.886–5.534	0.089	1.660	0.646–4.268	0.293
Differentiation (high/non-high)	1.892	0.758–4.727	0.172
PD-L1 (positive/negative)	0.701	0.373–1.318	0.270
CD8⁺ TIL (positive/negative)	0.825	0.476–1.430	0.493
TMB (> median/≤ median)	1.366	0.824–2.263	0.227
PD-L1 negative and TMB > median VS. others	1.591	0.960–2.638	0.100	1.425	0.822–2.468	0.207
PD-L1 negative and TMB ≤ median VS. others	0.818	0.485–1.380	0.452
PD-L1 positive and TMB ≤ median VS. others	0.707	0.283–1.765	0.457
PD-L1 positive and TMB > median VS. others	0.753	0.343–1.656	0.481
CD8⁺ TIL negative and TMB > median VS. others	1.785	0.929–3.341	0.078	1.652	0.811–3.364	0.166
CD8⁺ TIL negative and TMB ≤ median VS. others	0.753	0.343–1.654	0.480
CD8⁺ TIL positive and TMB ≤ median VS. others	0.819	0.480–1.398	0.464
CD8⁺ TIL positive and TMB > median VS. others	1.031	0.614–1.730	0.909

HR hazard ratio, CI confidence interval, PS performance score, TMB tumor mutation burden
^#Reduction of degrees of freedom due to constants or linear dependent variables

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Hematology & Oncology

Contact us